Clene submits NDA seeking accelerated approval of CNM-Au8 for ALS

Clene Inc. ($CLNN) has submitted a New Drug Application seeking accelerated approval of CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).

Detected & updated continuously · Source: Nebula